Newsletter and Current Position Update – 6/01/12
RIGHT NOW! IN THE CURRENT NEWSLETTER!
Six analysts rate this biotech a STRONG BUY or a BUY as it develops drugs for such diseases as lupus and has alliances with some big name pharmaceuticals; trading at around $2.00.
And six analysts also rate this biotech a STRONG BUY or a BUY as it develops products for treating central nervous system disorders; trading at under $3.00.
* Subscribers may now login to view the current newsletter.
* Not a subscriber? SUBSCRIBE TODAY!